Dr. Harrison on Choosing Frontline Treatment for RCC

Michael R. Harrison, MD
Published: Thursday, Nov 30, 2017



Michael R. Harrison, MD, assistant professor of medicine, Duke Cancer Institute, discusses choosing frontline treatment for patients with renal cell carcinoma (RCC).

Considering the data with cabozantinib (Cabometyx) versus ipilimumab (Yervoy) and nivolumab (Opdivo), the field is changing so rapidly. There is going to be data of those combinations with checkpoint inhibitors and anti-VEGF agents, but the future lies in other combinations, explains Harrison.

According to Harrison, axitinib (Inlyta) would also be reasonable since it has a second-line approval and is being investigated in clinical trials.
 
SELECTED
LANGUAGE


Michael R. Harrison, MD, assistant professor of medicine, Duke Cancer Institute, discusses choosing frontline treatment for patients with renal cell carcinoma (RCC).

Considering the data with cabozantinib (Cabometyx) versus ipilimumab (Yervoy) and nivolumab (Opdivo), the field is changing so rapidly. There is going to be data of those combinations with checkpoint inhibitors and anti-VEGF agents, but the future lies in other combinations, explains Harrison.

According to Harrison, axitinib (Inlyta) would also be reasonable since it has a second-line approval and is being investigated in clinical trials.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x